Probiodrug

Probiodrug is a biopharmaceutical company dedicated to the research and development of novel therapeutic solutions to treat people with Alzheimer’s Disease.

  • Probiodrug floated on Euronext Amsterdam with an initial market capitalisation of €102m
  • Proceeds of the offering will be used to execute the phase 2a study of its lead product in Alzheimer’s patients
  • Efforts resulted in an order book mainly made up of long-term specialist investors, despite turbulent markets
     
Disclaimer Kempen & Co Privacy statement Asset Management Privacy statement Merchant Banking Statement under the UK Modern Slavery Act Cookie Settings
Kempen & Co NV is part of Van Lanschot Kempen Van Lanschot